At present, the regulatory authorities do not consider the data obtained by testing the drugs on OOCs sufficient for approval. Data predicting the efficacy of a drug molecule obtained by the chips can be submitted but only along with the trial data from animal and human subjects for the approval process. These drug regulations limit the use of OCCs by end-users are expected to hinder the growth of the global organ-on-a-chip market. Several market players currently dominate the global organ-on-a-chip market. The key players are involved in product launches and acquisitions to strengthen their market positions.